SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: gissa_gamma who wrote (38520)1/10/2017 6:57:37 AM
From: li35113 Recommendations

Recommended By
drtom1234
erippetoe
patlawche11

   of 63310
 
> Cynthia Sullivan, Chief Executive Officer and President of the Company, will step down upon the Company’s filing for
> Accelerated Approval of IMMU-132 to the Food and Drug Administration, which is expected to occur in mid-2017.

The more I think about this, the more I realize that it's foolishness rooted in the company's inexperience. The milestone would not be filing for Accelerated Approval, it would be receiving Accelerated Approval. Between the two, FDA comes back at you with questions to answer—things on the application that need to be expanded and clarified.

So, which is it? Is Cindy a key person needed for the filing? If no, there's no reason for her to stick around. If yes, leaving after merely filing would create an information vacuum.

Hint: I'd rather have Peter Hutt (on the venBio slate) working on my FDA filing than Cindy Sullivan.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News